Review



mouse monoclonal anti ccnd1  (Cell Signaling Technology Inc)


Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Cell Signaling Technology Inc mouse monoclonal anti ccnd1
    Primer lists of Real-time PCR
    Mouse Monoclonal Anti Ccnd1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anti ccnd1/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse monoclonal anti ccnd1 - by Bioz Stars, 2024-12
    96/100 stars

    Images

    1) Product Images from "Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line"

    Article Title: Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line

    Journal: BMC Cancer

    doi: 10.1186/1471-2407-6-224

    Primer lists of Real-time PCR
    Figure Legend Snippet: Primer lists of Real-time PCR

    Techniques Used:

    Genes differently expressed in cisplatin resistant SCC cells
    Figure Legend Snippet: Genes differently expressed in cisplatin resistant SCC cells

    Techniques Used: Transduction

    Validation of genechip results by Real-time PCR and Western blotting . A: Using Real-time PCR, we validated the expression of MAP2K6, RECQL, CCND1, CCND3, ABCB1, ABCC2 and GST-Pi transcripts in both cell lines and calculated the relative fold changes by normalizing against GAPDH expression. Ratios of transcripts in Tca/cisplatin cells and Tca8113 cells generally showed the same expression differences as microarray analysis. Each column represents the results of an independent experiment (repeated three times). B: Using Western blotting, we further validated the expression of CCND1, CCND3, ABCB1 and GST-Pi proteins in both cell lines, using β-actin as a loading control. The results also show alterations similar to those found using the genechip. Each figure represents three independent experiments. (a: Tca/cisplatin cells, b:Tca8113 cells).
    Figure Legend Snippet: Validation of genechip results by Real-time PCR and Western blotting . A: Using Real-time PCR, we validated the expression of MAP2K6, RECQL, CCND1, CCND3, ABCB1, ABCC2 and GST-Pi transcripts in both cell lines and calculated the relative fold changes by normalizing against GAPDH expression. Ratios of transcripts in Tca/cisplatin cells and Tca8113 cells generally showed the same expression differences as microarray analysis. Each column represents the results of an independent experiment (repeated three times). B: Using Western blotting, we further validated the expression of CCND1, CCND3, ABCB1 and GST-Pi proteins in both cell lines, using β-actin as a loading control. The results also show alterations similar to those found using the genechip. Each figure represents three independent experiments. (a: Tca/cisplatin cells, b:Tca8113 cells).

    Techniques Used: Real-time Polymerase Chain Reaction, Western Blot, Expressing, Microarray

    Expression of CCND1 and CCND3 in primary oral squamous cell carcinoma . Fifty specimens of primary oral squamous cell carcinoma were collected and classified into resistant (red column) and sensitive (blue column) groups on the basis of growth inhibition as assessed by the modified MTT assay, 25 cases in each group. A. Immunstaining results were ranked according to the staining percentage: '-' (0–5%), '+'(5%-20%), '++' (20%-50%) and '+++' (>50%). B. Mann-Whitney U test showed that CCND1 ( P = 0.021) and CCND3 ( P = 0.013) were differentially expressed in primary tumors in a manner consistent with their drug resistance patterns.
    Figure Legend Snippet: Expression of CCND1 and CCND3 in primary oral squamous cell carcinoma . Fifty specimens of primary oral squamous cell carcinoma were collected and classified into resistant (red column) and sensitive (blue column) groups on the basis of growth inhibition as assessed by the modified MTT assay, 25 cases in each group. A. Immunstaining results were ranked according to the staining percentage: '-' (0–5%), '+'(5%-20%), '++' (20%-50%) and '+++' (>50%). B. Mann-Whitney U test showed that CCND1 ( P = 0.021) and CCND3 ( P = 0.013) were differentially expressed in primary tumors in a manner consistent with their drug resistance patterns.

    Techniques Used: Expressing, Inhibition, Modification, MTT Assay, Staining, MANN-WHITNEY



    Similar Products

    86
    Santa Cruz Biotechnology mouse anti cyclin d1 ccnd1 monoclonal antibody
    Involvement with apoptosis and cell cycle by treatment with of SE against at RA in HEPM cells Fig. 3A: Apotracker staining (green) of HEPM cells after treatment with 100 μM at RA and 0.03% SE for 48 h. The nuclei were counterstained with Hoechst 33342 (blue). Scale bar, 50 μm. Fig. 3B: Immunoblotting of HEPM cells after treatment with 100 μM at RA and 0.03% SE for 48 h. β-actin was served as an internal control. *p < 0.05 and ***p < 0.001 versus at RA. at RA: all-trans -retinoic acid HEPM: human embryonic palatal mesenchymal SE: Sasa veitchii extract <t>CCND1:</t> <t>cyclin</t> <t>D1</t>
    Mouse Anti Cyclin D1 Ccnd1 Monoclonal Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti cyclin d1 ccnd1 monoclonal antibody/product/Santa Cruz Biotechnology
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse anti cyclin d1 ccnd1 monoclonal antibody - by Bioz Stars, 2024-12
    86/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology mouse anti human monoclonal ccnd1
    miR-623 directly targets <t>cyclin</t> <t>D1</t> <t>(CCND1)</t> in GC. (A) Wild-type (WT) and mutated (MUT) miR-623 binding sequences in the 3′-untranslated region (3′-UTR) of CCND1. (B) RT-qPCR and (C) Western blot were performed to determine the mRNA and protein levels of CCND1 in SGC-7901 and BGC-823 cells transfected with miR-623 mimic or miR-NC. * p < 0.05 compared with miR-NC. miR-623 or miR-NC was transfected in (D) SGC-7901 and (E) BGC-823 cells with psiCHECK-WT-CCND1-3′-UTR or psiCHECK-MUT-CCND1-3′-UTR. Relative luciferase activity levels were measured at 48 h posttransfection. * p < 0.05 compared with miR-NC.
    Mouse Anti Human Monoclonal Ccnd1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human monoclonal ccnd1/product/Santa Cruz Biotechnology
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse anti human monoclonal ccnd1 - by Bioz Stars, 2024-12
    96/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc mouse monoclonal anti ccnd1
    Primer lists of Real-time PCR
    Mouse Monoclonal Anti Ccnd1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anti ccnd1/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse monoclonal anti ccnd1 - by Bioz Stars, 2024-12
    96/100 stars
      Buy from Supplier

    86
    Proteintech anti ccnd1 mouse monoclonal antibody
    Primer lists of Real-time PCR
    Anti Ccnd1 Mouse Monoclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti ccnd1 mouse monoclonal antibody/product/Proteintech
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti ccnd1 mouse monoclonal antibody - by Bioz Stars, 2024-12
    86/100 stars
      Buy from Supplier

    86
    Bioss anti ccnd1 mouse monoclonal antibody
    Primer lists of Real-time PCR
    Anti Ccnd1 Mouse Monoclonal Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti ccnd1 mouse monoclonal antibody/product/Bioss
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti ccnd1 mouse monoclonal antibody - by Bioz Stars, 2024-12
    86/100 stars
      Buy from Supplier

    93
    OriGene cyclin d1 ta801655
    Primer lists of Real-time PCR
    Cyclin D1 Ta801655, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cyclin d1 ta801655/product/OriGene
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cyclin d1 ta801655 - by Bioz Stars, 2024-12
    93/100 stars
      Buy from Supplier

    Image Search Results


    Involvement with apoptosis and cell cycle by treatment with of SE against at RA in HEPM cells Fig. 3A: Apotracker staining (green) of HEPM cells after treatment with 100 μM at RA and 0.03% SE for 48 h. The nuclei were counterstained with Hoechst 33342 (blue). Scale bar, 50 μm. Fig. 3B: Immunoblotting of HEPM cells after treatment with 100 μM at RA and 0.03% SE for 48 h. β-actin was served as an internal control. *p < 0.05 and ***p < 0.001 versus at RA. at RA: all-trans -retinoic acid HEPM: human embryonic palatal mesenchymal SE: Sasa veitchii extract CCND1: cyclin D1

    Journal: Nagoya Journal of Medical Science

    Article Title: Protective effect of Sasa veitchii extract against all-trans-retinoic acid-induced inhibition of proliferation of cultured human palate cells

    doi: 10.18999/nagjms.86.2.223

    Figure Lengend Snippet: Involvement with apoptosis and cell cycle by treatment with of SE against at RA in HEPM cells Fig. 3A: Apotracker staining (green) of HEPM cells after treatment with 100 μM at RA and 0.03% SE for 48 h. The nuclei were counterstained with Hoechst 33342 (blue). Scale bar, 50 μm. Fig. 3B: Immunoblotting of HEPM cells after treatment with 100 μM at RA and 0.03% SE for 48 h. β-actin was served as an internal control. *p < 0.05 and ***p < 0.001 versus at RA. at RA: all-trans -retinoic acid HEPM: human embryonic palatal mesenchymal SE: Sasa veitchii extract CCND1: cyclin D1

    Article Snippet: Rabbit anti-cleaved caspase-3 polyclonal antibody (1:2,500 dilution; Cell Signaling Technology, Beverly, MA), mouse anti-cyclin D1 (CCND1) monoclonal antibody (1:1,000 dilution; Santa Cruz Biotechnology, Dallas, TX), mouse anti-CCNA (1:1,000 dilution; Santa Cruz Biotechnology), anti-mouse CCNB (1:1,000 dilution; Santa Cruz Biotechnology), anti-mouse CCNE (1:1,000 dilution; Santa Cruz Biotechnology), and anti-mouse β-actin monoclonal antibody (1:2,500 dilution; MBL, Aichi, Japan) were used as primary antibodies for immunoblotting.

    Techniques: Staining, Western Blot, Control

    Proposed mechanism of SE against at RA-induced cell proliferation inhibition ERBB2: Erb-B2 receptor tyrosine kinase 2 JADE1 : jade family PHD finger 1 CCND1: cyclin D1

    Journal: Nagoya Journal of Medical Science

    Article Title: Protective effect of Sasa veitchii extract against all-trans-retinoic acid-induced inhibition of proliferation of cultured human palate cells

    doi: 10.18999/nagjms.86.2.223

    Figure Lengend Snippet: Proposed mechanism of SE against at RA-induced cell proliferation inhibition ERBB2: Erb-B2 receptor tyrosine kinase 2 JADE1 : jade family PHD finger 1 CCND1: cyclin D1

    Article Snippet: Rabbit anti-cleaved caspase-3 polyclonal antibody (1:2,500 dilution; Cell Signaling Technology, Beverly, MA), mouse anti-cyclin D1 (CCND1) monoclonal antibody (1:1,000 dilution; Santa Cruz Biotechnology, Dallas, TX), mouse anti-CCNA (1:1,000 dilution; Santa Cruz Biotechnology), anti-mouse CCNB (1:1,000 dilution; Santa Cruz Biotechnology), anti-mouse CCNE (1:1,000 dilution; Santa Cruz Biotechnology), and anti-mouse β-actin monoclonal antibody (1:2,500 dilution; MBL, Aichi, Japan) were used as primary antibodies for immunoblotting.

    Techniques: Inhibition

    miR-623 directly targets cyclin D1 (CCND1) in GC. (A) Wild-type (WT) and mutated (MUT) miR-623 binding sequences in the 3′-untranslated region (3′-UTR) of CCND1. (B) RT-qPCR and (C) Western blot were performed to determine the mRNA and protein levels of CCND1 in SGC-7901 and BGC-823 cells transfected with miR-623 mimic or miR-NC. * p < 0.05 compared with miR-NC. miR-623 or miR-NC was transfected in (D) SGC-7901 and (E) BGC-823 cells with psiCHECK-WT-CCND1-3′-UTR or psiCHECK-MUT-CCND1-3′-UTR. Relative luciferase activity levels were measured at 48 h posttransfection. * p < 0.05 compared with miR-NC.

    Journal: Oncology Research

    Article Title: MicroRNA-623 Targets Cyclin D1 to Inhibit Cell Proliferation and Enhance the Chemosensitivity of Cells to 5-Fluorouracil in Gastric Cancer

    doi: 10.3727/096504018X15193469240508

    Figure Lengend Snippet: miR-623 directly targets cyclin D1 (CCND1) in GC. (A) Wild-type (WT) and mutated (MUT) miR-623 binding sequences in the 3′-untranslated region (3′-UTR) of CCND1. (B) RT-qPCR and (C) Western blot were performed to determine the mRNA and protein levels of CCND1 in SGC-7901 and BGC-823 cells transfected with miR-623 mimic or miR-NC. * p < 0.05 compared with miR-NC. miR-623 or miR-NC was transfected in (D) SGC-7901 and (E) BGC-823 cells with psiCHECK-WT-CCND1-3′-UTR or psiCHECK-MUT-CCND1-3′-UTR. Relative luciferase activity levels were measured at 48 h posttransfection. * p < 0.05 compared with miR-NC.

    Article Snippet: In this study, mouse anti-human monoclonal CCND1 (1:1,000 dilution; Catalog No. sc-8396) and mouse anti-human monoclonal β-actin (1:1,000 dilution; Catalog No. sc-81178) primary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). β-Actin was utilized as a loading control for protein level normalization.

    Techniques: Binding Assay, Quantitative RT-PCR, Western Blot, Transfection, Luciferase, Activity Assay

    CCND1 overexpression in GC tissues is inversely correlated with miR-623 level. (A) RT-qPCR and (B) Western blot were applied to measure the mRNA and protein expression levels of CCND1 in GC tissues and adjacent normal tissues, respectively. * p < 0.05 compared with normal tissues. (C) The association between CCND1 mRNA and miR-623 levels in GC tissues was assessed through Spearman’s correlation analysis. r = −0.5849, p = 0.0005.

    Journal: Oncology Research

    Article Title: MicroRNA-623 Targets Cyclin D1 to Inhibit Cell Proliferation and Enhance the Chemosensitivity of Cells to 5-Fluorouracil in Gastric Cancer

    doi: 10.3727/096504018X15193469240508

    Figure Lengend Snippet: CCND1 overexpression in GC tissues is inversely correlated with miR-623 level. (A) RT-qPCR and (B) Western blot were applied to measure the mRNA and protein expression levels of CCND1 in GC tissues and adjacent normal tissues, respectively. * p < 0.05 compared with normal tissues. (C) The association between CCND1 mRNA and miR-623 levels in GC tissues was assessed through Spearman’s correlation analysis. r = −0.5849, p = 0.0005.

    Article Snippet: In this study, mouse anti-human monoclonal CCND1 (1:1,000 dilution; Catalog No. sc-8396) and mouse anti-human monoclonal β-actin (1:1,000 dilution; Catalog No. sc-81178) primary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). β-Actin was utilized as a loading control for protein level normalization.

    Techniques: Over Expression, Quantitative RT-PCR, Western Blot, Expressing

    CCND1 overexpression reverses the effects of miR-623 on GC cells. (A) CCND1 protein expression was detected in SGC-7901 and BGC-823 cells cotransfected with miR-623 mimic and pcDNA3.1 or pcDNA3.1-CCND1 through Western blot. * p < 0.05 compared with miR-NC. # p < 0.05 compared with miR-623 mimics + pDNA3.1-CCND1. CCK-8 assay (B), cell chemosensitivity assay (C), and flow cytometry analysis of cell apoptosis (D) were performed to determine cell proliferation, chemosensitivity to 5-FU, and apoptosis induced by 5-FU in differently treated SGC-7901 and BGC-823 cells, respectively. * p < 0.05 compared with miR-NC. # p < 0.05 compared with miR-623 mimics + pcDNA3.1-CCND1.

    Journal: Oncology Research

    Article Title: MicroRNA-623 Targets Cyclin D1 to Inhibit Cell Proliferation and Enhance the Chemosensitivity of Cells to 5-Fluorouracil in Gastric Cancer

    doi: 10.3727/096504018X15193469240508

    Figure Lengend Snippet: CCND1 overexpression reverses the effects of miR-623 on GC cells. (A) CCND1 protein expression was detected in SGC-7901 and BGC-823 cells cotransfected with miR-623 mimic and pcDNA3.1 or pcDNA3.1-CCND1 through Western blot. * p < 0.05 compared with miR-NC. # p < 0.05 compared with miR-623 mimics + pDNA3.1-CCND1. CCK-8 assay (B), cell chemosensitivity assay (C), and flow cytometry analysis of cell apoptosis (D) were performed to determine cell proliferation, chemosensitivity to 5-FU, and apoptosis induced by 5-FU in differently treated SGC-7901 and BGC-823 cells, respectively. * p < 0.05 compared with miR-NC. # p < 0.05 compared with miR-623 mimics + pcDNA3.1-CCND1.

    Article Snippet: In this study, mouse anti-human monoclonal CCND1 (1:1,000 dilution; Catalog No. sc-8396) and mouse anti-human monoclonal β-actin (1:1,000 dilution; Catalog No. sc-81178) primary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). β-Actin was utilized as a loading control for protein level normalization.

    Techniques: Over Expression, Expressing, Western Blot, CCK-8 Assay, Flow Cytometry

    Primer lists of Real-time PCR

    Journal: BMC Cancer

    Article Title: Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line

    doi: 10.1186/1471-2407-6-224

    Figure Lengend Snippet: Primer lists of Real-time PCR

    Article Snippet: The first antibodies were: mouse monoclonal anti-CCND1 (Cell Signaling, clone DCS6, dilution 1:2000), rabbit polyclonal anti-CCND3 (Proteintech Group, dilution 1:1000), mouse monoclonal anti-ABCB1 (Calbiochem, clone C219, dilution 1:1000) and mouse monoclonal anti-GST-Pi (Abcam, clone BD1340, dilution 1:1000).

    Techniques:

    Genes differently expressed in cisplatin resistant SCC cells

    Journal: BMC Cancer

    Article Title: Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line

    doi: 10.1186/1471-2407-6-224

    Figure Lengend Snippet: Genes differently expressed in cisplatin resistant SCC cells

    Article Snippet: The first antibodies were: mouse monoclonal anti-CCND1 (Cell Signaling, clone DCS6, dilution 1:2000), rabbit polyclonal anti-CCND3 (Proteintech Group, dilution 1:1000), mouse monoclonal anti-ABCB1 (Calbiochem, clone C219, dilution 1:1000) and mouse monoclonal anti-GST-Pi (Abcam, clone BD1340, dilution 1:1000).

    Techniques: Transduction

    Validation of genechip results by Real-time PCR and Western blotting . A: Using Real-time PCR, we validated the expression of MAP2K6, RECQL, CCND1, CCND3, ABCB1, ABCC2 and GST-Pi transcripts in both cell lines and calculated the relative fold changes by normalizing against GAPDH expression. Ratios of transcripts in Tca/cisplatin cells and Tca8113 cells generally showed the same expression differences as microarray analysis. Each column represents the results of an independent experiment (repeated three times). B: Using Western blotting, we further validated the expression of CCND1, CCND3, ABCB1 and GST-Pi proteins in both cell lines, using β-actin as a loading control. The results also show alterations similar to those found using the genechip. Each figure represents three independent experiments. (a: Tca/cisplatin cells, b:Tca8113 cells).

    Journal: BMC Cancer

    Article Title: Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line

    doi: 10.1186/1471-2407-6-224

    Figure Lengend Snippet: Validation of genechip results by Real-time PCR and Western blotting . A: Using Real-time PCR, we validated the expression of MAP2K6, RECQL, CCND1, CCND3, ABCB1, ABCC2 and GST-Pi transcripts in both cell lines and calculated the relative fold changes by normalizing against GAPDH expression. Ratios of transcripts in Tca/cisplatin cells and Tca8113 cells generally showed the same expression differences as microarray analysis. Each column represents the results of an independent experiment (repeated three times). B: Using Western blotting, we further validated the expression of CCND1, CCND3, ABCB1 and GST-Pi proteins in both cell lines, using β-actin as a loading control. The results also show alterations similar to those found using the genechip. Each figure represents three independent experiments. (a: Tca/cisplatin cells, b:Tca8113 cells).

    Article Snippet: The first antibodies were: mouse monoclonal anti-CCND1 (Cell Signaling, clone DCS6, dilution 1:2000), rabbit polyclonal anti-CCND3 (Proteintech Group, dilution 1:1000), mouse monoclonal anti-ABCB1 (Calbiochem, clone C219, dilution 1:1000) and mouse monoclonal anti-GST-Pi (Abcam, clone BD1340, dilution 1:1000).

    Techniques: Real-time Polymerase Chain Reaction, Western Blot, Expressing, Microarray

    Expression of CCND1 and CCND3 in primary oral squamous cell carcinoma . Fifty specimens of primary oral squamous cell carcinoma were collected and classified into resistant (red column) and sensitive (blue column) groups on the basis of growth inhibition as assessed by the modified MTT assay, 25 cases in each group. A. Immunstaining results were ranked according to the staining percentage: '-' (0–5%), '+'(5%-20%), '++' (20%-50%) and '+++' (>50%). B. Mann-Whitney U test showed that CCND1 ( P = 0.021) and CCND3 ( P = 0.013) were differentially expressed in primary tumors in a manner consistent with their drug resistance patterns.

    Journal: BMC Cancer

    Article Title: Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line

    doi: 10.1186/1471-2407-6-224

    Figure Lengend Snippet: Expression of CCND1 and CCND3 in primary oral squamous cell carcinoma . Fifty specimens of primary oral squamous cell carcinoma were collected and classified into resistant (red column) and sensitive (blue column) groups on the basis of growth inhibition as assessed by the modified MTT assay, 25 cases in each group. A. Immunstaining results were ranked according to the staining percentage: '-' (0–5%), '+'(5%-20%), '++' (20%-50%) and '+++' (>50%). B. Mann-Whitney U test showed that CCND1 ( P = 0.021) and CCND3 ( P = 0.013) were differentially expressed in primary tumors in a manner consistent with their drug resistance patterns.

    Article Snippet: The first antibodies were: mouse monoclonal anti-CCND1 (Cell Signaling, clone DCS6, dilution 1:2000), rabbit polyclonal anti-CCND3 (Proteintech Group, dilution 1:1000), mouse monoclonal anti-ABCB1 (Calbiochem, clone C219, dilution 1:1000) and mouse monoclonal anti-GST-Pi (Abcam, clone BD1340, dilution 1:1000).

    Techniques: Expressing, Inhibition, Modification, MTT Assay, Staining, MANN-WHITNEY